CVS Health Corp (CVS) Shares Bought by Daiwa Securities Group Inc.

Daiwa Securities Group Inc. raised its position in shares of CVS Health Corp (NYSE:CVS) by 3.2% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 82,960 shares of the pharmacy operator’s stock after buying an additional 2,568 shares during the period. Daiwa Securities Group Inc.’s holdings in CVS Health were worth $6,530,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Camarda Financial Advisors LLC purchased a new position in shares of CVS Health during the second quarter worth $102,000. Canton Hathaway LLC purchased a new position in shares of CVS Health during the third quarter worth $126,000. Kiley Juergens Wealth Management LLC purchased a new position in shares of CVS Health during the second quarter worth $103,000. MCF Advisors LLC boosted its position in shares of CVS Health by 284.1% during the third quarter. MCF Advisors LLC now owns 1,713 shares of the pharmacy operator’s stock worth $135,000 after buying an additional 1,267 shares during the period. Finally, Legacy Advisors LLC boosted its position in shares of CVS Health by 7,100.0% during the second quarter. Legacy Advisors LLC now owns 1,800 shares of the pharmacy operator’s stock worth $116,000 after buying an additional 1,775 shares during the period. Institutional investors and hedge funds own 82.42% of the company’s stock.

In other CVS Health news, EVP Lisa Bisaccia sold 21,534 shares of the firm’s stock in a transaction on Monday, October 1st. The stock was sold at an average price of $80.00, for a total value of $1,722,720.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Eva C. Boratto sold 13,311 shares of the firm’s stock in a transaction on Monday, September 17th. The shares were sold at an average price of $77.16, for a total value of $1,027,076.76. Following the completion of the sale, the executive vice president now owns 55,162 shares in the company, valued at $4,256,299.92. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 43,409 shares of company stock worth $3,392,097. 0.53% of the stock is owned by insiders.

NYSE:CVS opened at $79.83 on Friday. The firm has a market capitalization of $81.55 billion, a P/E ratio of 13.53, a P/E/G ratio of 1.07 and a beta of 0.98. CVS Health Corp has a 12-month low of $60.14 and a 12-month high of $83.88. The company has a quick ratio of 1.87, a current ratio of 2.44 and a debt-to-equity ratio of 1.66.

CVS Health (NYSE:CVS) last released its earnings results on Tuesday, November 6th. The pharmacy operator reported $1.73 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.71 by $0.02. The firm had revenue of $47.27 billion during the quarter, compared to analyst estimates of $47.22 billion. CVS Health had a return on equity of 18.69% and a net margin of 1.65%. CVS Health’s revenue was up 2.4% compared to the same quarter last year. During the same period last year, the business posted $1.50 earnings per share. Equities research analysts predict that CVS Health Corp will post 7.04 earnings per share for the current year.

The firm also recently declared a quarterly dividend, which was paid on Thursday, November 1st. Shareholders of record on Wednesday, October 24th were paid a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a yield of 2.51%. The ex-dividend date was Tuesday, October 23rd. CVS Health’s dividend payout ratio is presently 33.90%.

CVS has been the subject of a number of recent research reports. Bank of America lifted their target price on CVS Health from $86.00 to $90.00 and gave the company a “buy” rating in a report on Monday, September 17th. ValuEngine lowered CVS Health from a “sell” rating to a “strong sell” rating in a report on Tuesday, September 4th. Royal Bank of Canada lifted their target price on CVS Health to $101.00 and gave the company an “outperform” rating in a report on Tuesday, September 18th. Tigress Financial reiterated a “buy” rating on shares of CVS Health in a report on Friday, October 26th. Finally, Leerink Swann set a $80.00 target price on CVS Health and gave the company an “outperform” rating in a report on Thursday, August 9th. One research analyst has rated the stock with a sell rating, five have issued a hold rating, ten have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $89.38.

ILLEGAL ACTIVITY NOTICE: “CVS Health Corp (CVS) Shares Bought by Daiwa Securities Group Inc.” was reported by WKRB News and is the sole property of of WKRB News. If you are accessing this piece on another domain, it was illegally copied and reposted in violation of United States and international copyright law. The original version of this piece can be viewed at https://www.wkrb13.com/2018/11/11/cvs-health-corp-cvs-shares-bought-by-daiwa-securities-group-inc.html.

CVS Health Profile

CVS Health Corporation, together with its subsidiaries, provides integrated pharmacy health care services. It operates through Pharmacy Services and Retail/LTC segments. The Pharmacy Services segment offers pharmacy benefit management solutions, such as plan design and administration, formulary management, Medicare Part D services, mail order, specialty pharmacy and infusion services, retail pharmacy network management services, prescription management systems, clinical services, disease management programs, and medical pharmacy management services.

Recommended Story: Trading Penny Stocks

Institutional Ownership by Quarter for CVS Health (NYSE:CVS)

Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply